BPC-157
10 mg vial, 60 capsules
Short answer first. Any retatrutide pill and tablets you come across online are not something a trial has ever tested, because no oral form exists. Every retatrutide study that has been published or registered gives the drug as a weekly injection under the skin, Eli Lilly has never announced a version you swallow, and the TGA has already caught counterfeit retatrutide for sale in Australia.
Is there a retatrutide pill hiding somewhere in the clinical programme? There is not, and nothing suggests one is coming. During development the compound carried the code LY3437943. It is an investigational agonist that hits three receptors at once (GLP-1, GIP and glucagon), and every efficacy study to date has delivered it by subcutaneous injection once a week. Jastreboff's group used it in NEJM's 2023 phase 2 obesity paper, Rosenstock's group used it in The Lancet's 2023 phase 2 diabetes paper, and so did the phase 3 TRANSCEND and TRIUMPH programmes, which reported through 2026.
When we went through the ClinicalTrials.gov registry for this guide (September 2026), the listed retatrutide studies all described the intervention as a subcutaneous injection. The word oral shows up in just one kind of entry, the drug interaction study, where volunteers swallowed another medicine (metoprolol is one example) on top of injected retatrutide so researchers could see if its absorption shifted. Not one study tests a retatrutide capsule or tablet.
Lilly's own timetable agrees. A July 2026 update declared phase 3 complete and flagged a US submission for early 2027, Q1 to be exact, built around the weekly shot. For a primer on the molecule, see what retatrutide is and how the triple agonist works.
Think about what retatrutide actually is. Chemically it is a chain of 39 amino acids with a molecular weight near 4,700, fitted with a C20 fatty diacid side chain. That side chain grips albumin in the blood, stretching the half-life far enough for once-weekly dosing. The very features that make it last are the ones that make oral retatrutide such a tough ask.
For that reason tirzepatide, semaglutide, insulin and retatrutide were all first developed as injections, which avoid the gut altogether. The limit is chemical, not a marketing decision, and it means a retatrutide pill is not something you can make by compressing the powder.
Only one GLP-1 peptide has ever been made to work by mouth, semaglutide, and the effort it took is telling. Rybelsus, the Novo Nordisk tablet, mixes semaglutide with an absorption enhancer called salcaprozate sodium, or SNAC. As the tablet dissolves, this enhancer raises the local pH to keep pepsin at bay and eases the peptide across the gastric wall, the site where nearly all uptake takes place.
Even with that help, absolute bioavailability for the first Rybelsus tablets is given in the US label as about 0.4 to 1%. Put another way, more than 99% of each tablet's peptide is lost. That forces a far bigger amount of drug into every tablet compared with a weekly shot, plus strict fasting conditions so uptake stays predictable. Here in Australia, the TGA approved Rybelsus in 2022 and it sits on the ARTG for type 2 diabetes. In December 2025 the FDA in the US cleared a stronger oral semaglutide tablet for weight management (the Wegovy pill) after the OASIS 4 trial.
What does that mean for retatrutide? Semaglutide only became a tablet after years of molecule-specific formulation science, and nobody has published anything similar for retatrutide. A seller who simply loads retatrutide into a capsule, minus an enhancer and minus a validated formula, cannot point to any proof that a single microgram gets absorbed.
Plenty of the talk about oral retatrutide is really a mix-up with Lilly's new weight loss tablet. That tablet is real, but it contains a different drug. Orforglipron is not a peptide at all. It is a small molecule with a weight of about 880 and switches on the GLP-1 receptor alone. Being small, it gets through digestion intact and is absorbed like any ordinary tablet, without the fasting rules that oral semaglutide demands.
A fair side-by-side, then, sets retatrutide (three receptors, weekly injection, still investigational) against orforglipron (GLP-1 only, daily tablet, approved in the US). Cross-trial comparisons are rough, but ATTAIN-1 recorded less weight loss for orforglipron than retatrutide recorded across its own phase 2 and 3 trials. On the injectable front, see our page on retatrutide against tirzepatide.
If oral retatrutide has never appeared in a trial, what exactly are the retatrutide tablets and capsules being advertised? None of the sellers has said. There is no validated oral product to copy, no data showing absorption and no reference standard describing what a functioning tablet would hold.
Australian regulators have already seen how badly unverified retatrutide can go. In September 2026 the TGA reported lab results on a product labelled retatrutide, tested after a patient with uncontrollable vomiting was hospitalised with a torn oesophagus. There was no retatrutide in it. What it did hold was semaglutide that the label never mentioned, at roughly eight times the strength the TGA has measured in semaglutide products it has reviewed. The regulator's message is blunt. Retatrutide sourced away from a clinical trial might be fake and should not be used outside a trial setting. Months before that, the Victorian Department of Health reported acute liver injury in people taking unapproved products labelled retatrutide.
Putting a peptide into a capsule or tablet makes checking it harder, not easier. Binders, fillers and coatings get in the way of testing, and you cannot tell anything about the peptide's state by looking at a pill. We apply one rule. No lot-specific mass spectrometry identity data, no trust, and a retatrutide pill stays unverified. Even with that data in hand, no publication shows the peptide gets absorbed by mouth. Our article is retatrutide available in Australia covers where things stand locally.
AminoLab refuses to stock retatrutide drops, capsules or tablets, because the evidence for an oral format is nil. Our stock mirrors what the papers used, freeze-dried (lyophilised) peptide intended for laboratory research.
Two independent checks are run on each lot. Identity comes from mass spectrometry, purity from HPLC, and both are explained on our quality testing process page. Reconstituting at the bench? Let the retatrutide reconstitution calculator do the sums for you.
Not sure which to choose? A first project usually begins with the 10 mg vial. Larger studies that want everything from a single lot can step up to 20 mg or 30 mg. The Retatrutide Starter Kit packs one vial, a small vial of diluent and one insulin syringe together. Order either format online, check your lot's certificate before checkout, and remember that oral retatrutide sold elsewhere has never been through a single trial.
This guide and every product it mentions are for laboratory research only. We give no advice here about dosing or administration, and AminoLab products must never be given to humans or animals. Related compounds are in our metabolic research peptides range.
No. All published and registered retatrutide trials use a subcutaneous injection given once a week, and Eli Lilly has announced no oral version. Anything sold online as a retatrutide pill or tablet lacks any clinical data, and the TGA cautions that product sourced away from a clinical trial could be fake.
Nothing published says it could. As a 39 amino acid peptide, retatrutide is broken down by digestive enzymes and hardly absorbed through the gut wall. The one GLP-1 peptide tablet on the market, semaglutide, needs SNAC as an enhancer and still absorbed at only about 0.4 to 1% in its first formulation.
It is not. Orforglipron is a different Eli Lilly medicine, a small molecule taken as a daily tablet that acts only on the GLP-1 receptor, while retatrutide is an injected peptide working on three receptors. US approval came in April 2026 under the name Foundayo, and the TGA was still evaluating it when this guide was written.
Only testing could tell, and there is no validated retatrutide tablet to measure them against. When the TGA tested a product labelled retatrutide in September 2026, there was no retatrutide inside, only a hefty undeclared semaglutide load. Without lot-specific mass spectrometry results, assume any such tablet is unverified.
Size and chemistry. Gut enzymes cleave peptide bonds, and at roughly 4,700 the molecule is too bulky to cross the intestinal lining in any useful amount. An injection under the skin skips the gut, which is why retatrutide has only been studied that way, as with tirzepatide and injectable semaglutide.
AminoLab offers it in two lab formats, a 10 mg pen or a lyophilised vial at 10, 20 or 30 mg, and never in tablet form, because oral retatrutide has no published trial data. Everything ships from Australian stock with a lot certificate covering mass spectrometry and HPLC, and it is sold for laboratory research only, never for human use.
10 mg vial, 60 capsules
50 mg vial, 100 mg vial
10 mg vial
3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe
Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.
Leave